News
Showing all blog posts in the News category.
Retatrutide Black Market, Late 2026: Lawsuits, FDA Letters, Counterfeits
Lilly sued six sellers, the FDA named 'GLP-3 Reta' in warning letters, grey-market users lost half the trial weight, and a counterfeit vial was 8x semaglutide.
TRIUMPH-2 and TRIUMPH-3 Results: Retatrutide in Diabetes and Heart Disease
Eli Lilly's July 23, 2026 readouts: -20.8% weight loss with type 2 diabetes, -22.6% with cardiovascular disease, dysesthesia 6-7%, and a BLA planned for Q1 2027.
TRIUMPH-1 Phase 3 Results: Retatrutide Delivers 28.3% Weight Loss in 2,339-Patient Obesity Trial
Eli Lilly's pivotal TRIUMPH-1 Phase 3 trial of retatrutide (May 21, 2026) reported 28.3% mean weight loss at 12 mg over 80 weeks, with 45.3% of participants losing 30%+ of body weight. Full results, safety profile, and what it means for the regulatory timeline.
Retatrutide in the Context of the GLP-1 Revolution
How retatrutide fits into the broader GLP-1 revolution that is transforming metabolic medicine, and what the competitive landscape means for the future of obesity and diabetes treatment.